We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
+18.38%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$3.71B
AUM Growth
-$281M
Cap. Flow
-$830M
Cap. Flow %
-22.37%
Top 10 Hldgs %
31.98%
Holding
127
New
29
Increased
29
Reduced
22
Closed
37

Top Buys

Rank Stock Value
1
KITE
Kite Pharma, Inc.
KITE
+$73.3M
2
MCK icon
McKesson
MCK
+$66.4M
3
NOW icon
ServiceNow
NOW
+$60.6M
4
DXC icon
DXC Technology
DXC
+$60M
5
MSFT icon
Microsoft
MSFT
+$58M

Top Sells

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$125M
2
MRVL icon
Marvell Technology
MRVL
+$118M
3
BIIB icon
Biogen
BIIB
+$102M
4
WFT
Weatherford International plc
WFT
+$102M
5
CSC
Computer Sciences
CSC
+$98M

Sector Composition

Rank Sector Weight
1 Healthcare 40.08%
2 Technology 13.76%
3 Consumer Discretionary 5.54%
4 Communication Services 4.09%
5 Financials 3.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
V icon
26
Visa
V
$677B
$52.7M 1.42%
561,690
+275,675
+96% +$25.6M
ACOR
27
DELISTED
Acorda Therapeutics
ACOR
$51M 1.37%
+21,568
New +$42.7M
HRTX icon
28
Heron Therapeutics
HRTX
$86.3M
$46.3M 1.25%
3,344,517
-588,213
-15% -$8.52M
META icon
29
Meta Platforms (Facebook)
META
$1.51T
$46.2M 1.25%
306,199
-27,292
-8% -$4.06M
MDCO
30
CALL
DELISTED
Medicines Co
MDCO
$42.1M 1.13%
1,107,200
+792,200
+251% +$35.3M
RVTY icon
31
Revvity
RVTY
$12.3B
$40.1M 1.08%
+588,540
New +$36.6M
CRM icon
32
Salesforce
CRM
$134B
$38.9M 1.05%
+448,700
New +$39.1M
GOOGL icon
33
Alphabet (Google) Class A
GOOGL
$3.91T
$38.5M 1.04%
+827,560
New +$38.7M
SPGI icon
34
S&P Global
SPGI
$126B
$37.8M 1.02%
+258,649
New +$35.9M
PEN icon
35
Penumbra
PEN
$12.5B
$37.5M 1.01%
427,005
+71,398
+20% +$6.06M
LBTYA icon
36
Liberty Global Class A
LBTYA
$3.28B
$37.1M 1%
1,155,765
-1,933,396
-63% -$61.9M
PANW icon
37
Palo Alto Networks
PANW
$264B
$35.8M 0.96%
1,604,994
-740,652
-32% -$15M
CLVS
38
DELISTED
Clovis Oncology, Inc.
CLVS
$34.7M 0.93%
370,141
-636,331
-63% -$38.9M
ZAYO
39
DELISTED
Zayo Group Holdings, Inc.
ZAYO
$33.7M 0.91%
1,089,069
+534,478
+96% +$17.5M
JD icon
40
JD.com
JD
$40.8B
$33.1M 0.89%
+842,701
New +$31.8M
AMT icon
41
American Tower
AMT
$77.7B
$30.2M 0.81%
228,350
+1,813
+0.8% +$232K
NTES icon
42
NetEase
NTES
$76.5B
$30M 0.81%
498,380
-135,050
-21% -$7.74M
ATVI
43
DELISTED
Activision Blizzard
ATVI
$28.4M 0.77%
+493,776
New +$27.3M
ELGX
44
DELISTED
Endologix Inc
ELGX
$27.2M 0.73%
559,947
+355,568
+174% +$20.9M
PBYI icon
45
CALL
Puma Biotechnology
PBYI
$406M
$27M 0.73%
+309,100
New +$17.3M
SPNC
46
DELISTED
Spectranetics Corp
SPNC
$25.9M 0.7%
675,383
-775,647
-53% -$22.4M
CHRS icon
47
Coherus Oncology
CHRS
$217M
$25.9M 0.7%
1,802,611
+302,929
+20% +$5.83M
ARAY icon
48
Accuray
ARAY
$28.4M
$22.9M 0.62%
4,816,334
+715,213
+17% +$3.14M
BOX icon
49
Box
BOX
$4.02B
$22.9M 0.62%
+1,253,879
New +$22.6M
MYOK
50
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$21.9M 0.59%
1,669,524
+131,017
+9% +$1.73M
1
2
3 4 5

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return
PRS
Pinkerton Retirement Specialists Coeur D Alene, Idaho $1.1B AUM 30.57% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
CF
Corebridge Financial Houston, Texas $1.09B AUM 1.85% 1-Year Est. Return
MIA
MMBG Investment Advisors Miami, Florida $1.09B AUM 30.96% 1-Year Est. Return

PFM Health Sciences's Q2 2017 Portfolio in Review

As of Q2 2017, PFM Health Sciences held 127 positions worth $3.71B, down 7% from $3.99B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

PFM Health Sciences withdrew a net $830M in Q2 2017, closing 37 positions and reducing 22 holdings. Its most notable exit was Jazz Pharmaceuticals, an estimated $125M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 40% of assets, up from 39% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, PFM Health Sciences opened a new position in McKesson worth $72.1M.

  • PFM Health Sciences's largest Q2 2017 buy was McKesson: 438,055 shares worth $72.1M.
  • PFM Health Sciences added most to Kite Pharma, Inc. in Q2 2017, an estimated $73.3M increase.
  • PFM Health Sciences's biggest Q2 2017 reduction was Marvell Technology, cutting an estimated $118M.
  • PFM Health Sciences fully exited Jazz Pharmaceuticals in Q2 2017, selling an estimated $125M.
  • PFM Health Sciences's ten largest holdings make up 32% of its $3.71B portfolio in Q2 2017.
  • PFM Health Sciences opened 29 new positions and closed 37 in Q2 2017.
  • PFM Health Sciences's portfolio value fell 7% quarter-over-quarter to $3.71B.

Based on PFM Health Sciences's 13F filing for Q2 2017, filed 14 Aug 2017.